Recipharm, the contract development and manufacturing organisation (CDMO), has announced a €3.7 million investment to expand its lyophilisation capacity in Masate, Italy, in response to growing customer demand.
The investment forms part of Recipharm’s strategy to become a leading lyophilisation provider, and is in addition to the ongoing investment at Recipharm in Wasserburg, Germany, where a further €32 million is currently being spent to increase capacity.
Specialising in aseptic manufacturing and filling of parenterals, Recipharm in Masate, located close to Milan, offers lyophilisation capabilities in both vials and ampoules. The investment will see the introduction of a new lyophiliser for vials, bringing the total number of machines from five to six and increasing the facility’s capacity by approximately 20 per cent.
The new machine will allow the CDMO to support more drug developers with their stability challenges and meet growing demand for its lyophilisation services, particularly in Europe, China and Japan.
Commenting on the investment, General Manager Giorgio Bruno said: “We are experiencing greater demand for lyophilisation capabilities from our customers, ranging from some of the largest pharmaceutical companies to small and mid-sized firms. As we continue to receive more requests from existing customers and new enquiries from drug developers in new territories, we needed to increase our capacity”.
For more information:
Last updated on: 26/08/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.